FLVCR2 and neoplasm: The TCGA database was established in 2006 and compiled gene expression and clinical data on 33 different tumor types, ranging from hematological to solid tumors and from mildly to severely aggressive tumors.[28] Considerable progress has been achieved using TCGA to identify novel oncogenic biomarkers and establish molecular subtypes.[29–31] Many other platforms, such as UALCAN and GEPIA 2.0, have been developed to identify CCT family genes that may serve as novel and useful biomarkers for the diagnosis of LUAD and targets for LUAD treatment.